HUGE - FSD Pharma launches research program for alcohol misuse; plans issue of warrants
- FSD Pharma ( NASDAQ: HUGE ) said it launched of a new research and development program focused on alcohol misuse.
- "FSD Pharma’s existing pipelines and research priorities in brain and inflammatory disorders, including mental health, provides a natural extension to investigate the effects of alcohol on the brain. Our clinical and product development teams are exploring how to limit and potentially reverse the negative effects of alcohol on brain function," said Lakshmi Kotra, CEO of Lucid Psycheceuticals, a unit of FSD Pharma.
- In addition, FSD said that it has agreed to issue common share purchase warrants to buy 800K shares of the company. The warrants will have a 13-month term with an exercise price ranging from $1.50 to $4.50.
For further details see:
FSD Pharma launches research program for alcohol misuse; plans issue of warrants